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A cardinal manifestation of cystic ﬁbrosis (CF) lung disease
is chronic infection. It is believed that this chronic infection
contributes signiﬁcantly to the progressive loss of lung
function and eventual respiratory failure, resulting in
premature death. Antibiotics are a common part of the
treatment of CF lung disease, and it can be argued that the
increased use of antibiotics over time has played a major
role in the improved health and survival of patients with CF.
Antibiotics are commonly used to treat exacerbations of
CF lung disease, but it is becoming increasingly clear that
exacerbations are associated with worse lung disease, and
recovery of lost lung function associated with exacerbations
may not be achievable. Therefore, chronic use of antibiotics
to suppress lung infection has become common practice and
is recommended in CF treatment guidelines.
Aerosolization is the most common method of chronic
treatment with antibiotics. Aerosol antibiotics have been
used for many years, and we now have formulations that
have been approved for use in patients with CF. The
treatment strategy used to develop these inhaled antibiotics
is one of intermittent therapy; i.e., month on–month off.
This strategy was chosen for the study of aerosolized
antibiotics, taking into account what was known at the
time about efﬁcacy and toxicity, as well as other potential
perceived adverse events such as selection of resistant
pathogens.
Since the approval of aerosol antibiotics using the regimen
of intermittent therapy, we have come to challenge this
strategy and ask whether it might be preferable to consider
continuous treatment with antibiotics. Continuous therapy is
not novel; similar treatment strategies have been reported
in Europe for some time, and many CF clinicians have
adopted this strategy when their patients do not thrive on
an intermittent treatment regimen.
This supplement provides a historical perspective on
the development of aerosol antibiotics and the treatment
strategies used in clinical trials. We then challenge
this strategy and offer compelling evidence to support
continuous treatment, but we must address whether this
is best accomplished using one drug or a rotation of
antibiotics. If we were to compare such strategies, we
must have measurable clinical outcomes, and such study
paradigms are presented here.
Finally, we accept that aerosolization of antibiotics adds
treatment burden, and patients may not be fully adherent
to this strategy. Methods to improve adherence, either by
technological advances or by behavioral modiﬁcation, are
also addressed here.
We hope readers will appreciate how we have come to the
current treatment paradigms using aerosolized antibiotics
and assess whether this strategy is accomplishing our goals
for our patients. If the answer is no, then we hope we have
addressed opportunities to improve on these outcomes.
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